|Videos|February 19, 2018

Pseudomonas aeruginosa: Current & Future Treatment Options

Author(s)Contagion&reg Editorial Staff

Marin H. Kollef, MD, discusses treatment options for Pseudomonas aeruginosa.

Marin H. Kollef, MD, professor of medicine and Virginia E. & Sam J. Golman chair of the Respiratory Intensive Care department of Washington University School of Medicine, discusses the current treatment options for Pseudomonas aeruginosa—piperacillin-tazobactam being the drug that is most commonly used in the United States. Dr. Kollef highlights other drugs that are also used for treatment, including cefcapene, aminoglycosides, and carbapenems. He also discusses 3 newer drugs available for the treatment of Pseudomonas infections.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Pseudomonas aeruginosa: Current & Future Treatment Options

Related Content

Important Clinical Practice Takeaways From the DOTs and PeterPen Trials

Considering Diversified Treatment Strategies to Combat Gonorrhea Resistance

Efflux Pump Inhibitor Restores Azithromycin Activity Against Multidrug-Resistant Gram-Negative Pathogens

Understanding the ERADICATE Trial Limitations and Key Takeaways

Reductions in Funding, Personnel Will Leave US Less Prepared for Future Infectious Disease Outbreaks

Latest CME

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Community Practice Connections™: 16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Interventional Dry Eye: A Stepwise Treatment & Management Approach

North Carolina Oncology Association

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Wyoming State Oncology Society

Montana State Oncology Society

24th Annual International Congress on the Future of Breast Cancer® East

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Radioligand Therapy 101: The Science Behind the Strategy

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Pathways to Progress: RAS in GI Cancers (Spotlight CE Session)

Tackling Barriers to Vaccine Uptake: Practical Strategies for Adult Immunization

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence

26th Annual International Lung Cancer Congress

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

MacTel Decoded: Rethinking Conventional Approaches With Novel Neuroprotective Strategies

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

(CME Track) Transforming DED Management in Breaking Thermal Barriers

20th Annual New York Lung Cancers Symposium®

43rd Annual CFS®: Innovative Cancer Therapy for Tomorrow™

Patient, Provider, and Caregiver Connection™: Individualizing Care in C3 Glomerulopathy – Understanding Patient Challenges and the Role of Innovative Treatment

Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Oncology Town Hall: Shaping the Future of ALL Treatment Through Innovation in T-Cell Therapies

ISGIO 2025: Early-Stage Colorectal Cancer

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Community Practice Connections™ Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, and Beyond!

ISGIO 2025: Pancreatic and Neuroendocrine Tumors

Burst CME™: Disease-Modifying vs. Curative Therapy – Which Way to Go in Sickle Cell Disease?